Home Tags Immunomedics

Tag: Immunomedics

Loretta Itri, M.D., Joins Immunomedics as Chief Medical Officer

Biotech company Immunomedics today confirmed the appointment of Loretta Itri, M.D. as Chief Medical Officer (CMO). In her new role, Itri, who has decades...

FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan

Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...

With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...

Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan

In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies had signed an exclusive license...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Seattle Genetics and Immunomedics Terminate License Agreement for Sacituzumab Govitecan

Seattle Genetics and Immunomedics today confirmed that they have terminated their Exclusive Global Licensing Agreement for sacituzumab govitecan (IMMU-132), Immunomedics breakthrough therapy candidate to...

Sacituzumab Govitecan Show Promising Results in Patients with Advanced Triple-negative Breast...

A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on...

Seattle Genetics to Lead Global Development, Manufacturing and Commercialization of Sacituzumab...

The global biotechnology company Seattle Genetics earlier today confirmed development and icencing agreement with Immunomedics. Under the terms of the agreement, Seattle Genetics receives...

New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program

Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...